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Purpose. To quantify liver adiposity using magnetic resonance imaging (MRI) and to determine its association with metabolic
profile in men with spinal cord injury (SCI).Materials and Methods. MRI analysis of liver adiposity by fat signal fraction (FSF) and
visceral adipose tissue (VAT) was completed on twenty participants. Intravenous glucose tolerance test was conducted to measure
glucose effectiveness (𝑆g) and insulin sensitivity (𝑆i). Lipid panel, fasting glucose, glycated hemoglobin (HbA1c), and inflammatory
cytokines were also analyzed. Results. Average hepatic FSF was 3.7% ± 2.1. FSF was positively related to TG, non-HDL-C, fasting
glucose, HbA1c, VAT, and tumor necrosis factor alpha (TNF-𝛼). FSF was negatively related to 𝑆i and testosterone. FSF was positively
related to VAT (𝑟 = 0.48, 𝑝 = 0.032) and TNF-𝛼 (𝑟 = 0.51, 𝑝 = 0.016) independent of age, level of injury (LOI), and time
since injury (TSI). The associations between FSF and metabolic profile were independent of VAT. Conclusions. MRI noninvasively
estimated hepatic adiposity in men with chronic SCI. FSF was associated with dysfunction in metabolic profile, central adiposity,
and inflammation. Importantly, liver adiposity influenced metabolic profile independently of VAT. These findings highlight the
significance of quantifying liver adiposity after SCI to attenuate the development of metabolic disorders.
1. Introduction
Metabolic dysfunction following spinal cord injury (SCI)
is characterized by a high prevalence of lipid disorders,
impaired glucose tolerance, and insulin resistance [1–3].
Metabolic dysfunction is linked to decreased muscle mass,
increased fat mass, and low anabolic hormones [1–10]. For
instance, 76% of individuals with SCI were shown to have
dyslipidemia [4] with another study showing that 50% of
individuals with paraplegia and 62% of those with tetraplegia
had impaired glucose tolerance [5]. Two-thirds of individuals
with SCI are overweight or obese regardless of a body mass
index (BMI) below 30 kg/m2, because BMI underestimates
the percentage of body fat in this population [3, 6–8]. Fur-
thermore, persons with SCI experience decreased anabolic
hormone levels, which is associated with abnormal lipid and
metabolic profiles. A previous study showed that 43% of
men with chronic SCI had low testosterone [9]. Therefore,
studying factors that may explain the high prevalence of
metabolic disease is clinically relevant to this population.
The associations between increased adipose tissue and
metabolic disorders are well established in the SCI popula-
tion. A previous study showed that an increase in trunk and
leg fatmass was related to deterioration of lipid andmetabolic
profile [10]. This confirmed earlier reports that showed that
intramuscular fat contributed to insulin resistance [11] and
predicted plasma glucose and type II diabetes in individuals
with SCI [12]. Furthermore, visceral adipose tissue (VAT) is
tightly linked to abnormal lipid and carbohydrate profiles
after SCI [10, 13]. Gorgey et al. showed thatVATwas positively
related to fasting plasma glucose and total cholesterol [10].
It appears that regional ectopic adiposity has detrimental
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effects on metabolic profile, but VAT or regional adiposity
did not entirely explain the variance inmetabolic dysfunction
after SCI [10]. This may be explained by the use of different
imaging techniques or failure to account for all depots of
ectopic adiposity. Therefore, accounting for different depots
of ectopic adiposity (VAT versus hepatic adiposity) may
provide insights on a range of metabolic disorders after SCI.
Magnetic resonance imaging (MRI) technology is a non-
invasive technique used to quantify adipose tissue depots
such as VAT, subcutaneous adipose tissue (SAT), intramus-
cular fat, and most recently bone marrow and liver adiposity
[14, 15]. This is extremely advantageous in understanding
the complexity of metabolic profile, since it remains unclear
how different adipose tissue depots contribute to metabolic
dysfunction after SCI. Studies have demonstrated that liver
adipose tissue is positively related to VAT and has also been
linked to the development of type II diabetes mellitus and
insulin resistance [16, 17]. Previous studies have speculated
that the release of inflammatory cytokines from ectopic
adipose tissue contributes to a state of chronic inflammation
and progression of metabolic disease [18]. Therefore, under-
standing the influence of various adipose tissue depots on
metabolic health is critical for elucidating the mechanisms
underlying the progression of metabolic disease. This may
allow for early interventions to prevent adverse health con-
sequences after SCI.
Abnormal amounts of liver adipose tissue that is not
explained by excessive alcohol consumption is known as non-
alcoholic fatty liver disease (NAFLD)—a term that encom-
passes steatosis, steatohepatitis, and cirrhosis [19]. Steatosis
is the simplest stage of NAFLD and is characterized as >5%
fatty-infiltrated hepatocytes [20]. Steatosis has a prevalence
of ∼30% in the general population [21] and ∼90% in the
obese population [22]. Recent studies have shown that
NAFLD is strongly associated with increased incidence of
metabolic syndrome, type II diabetes [23–25], and increased
inflammation [26–28]. Approximately 20%–50% of persons
with chronic SCI had abnormal fatty-infiltration of the liver
determined by ultrasound [29, 30] and animal studies of acute
SCI have documented increased liver inflammation [31, 32].
Liver fat can be quantified by liver biopsy, hydrogenmag-
netic resonance spectroscopy (1H-MRS), MRI, computed
tomography (CT), and ultrasound [33]. For years, the gold
standard for diagnosing NAFLD has been a liver biopsy.
However, the reliability of this invasive procedure has been
debated as it samples only ∼1/50,000 of the total liver mass
[20]. MRI provides a simple tool that allows for the detection
of liver fat. Quantifying liver adiposity by MRI relies on the
signal intensity of the in-phase (IP) and out-of-phase (OP)
images, where the IP image represents the signal intensity
of the sum of water and fat and the OP image represents
the difference of water and fat [34]. Fat signal fraction (FSF)
can be calculated from these values and has been shown to
be an accurate and reproducible technique to measure liver
fat content [33, 35, 36]. Previous studies have shown strong
correlations between FSF and histological liver fat content
[37, 38]. Increased FSF was observed in obese individuals
and decreased after weight loss [35, 37, 39]. Another study
revealed that FSF was associated with deterioration in lipid
Table 1: Physical characteristics of persons with motor complete
SCI.
Total, 𝑛 = 22 Tetra, 𝑛 = 8 Para, 𝑛 = 14
Demographics
Age, year 36.1 ± 10.0 37.5 ± 11.6 35.3 ± 9.4
Height, m 1.79 ± 0.06 1.80 ± 0.05 1.78 ± 0.07
Weight, kg 78.0 ± 13.0 75.0 ± 14.0 80.0 ± 13.0
BMI, kg/m2 24.6 ± 3.9 23.3 ± 4.5 25.3 ± 3.4
TSI, y 8.2 ± 7.9 7.9 ± 7.2 8.4 ± 8.5
Caucasian, n 14 6 8
African American, n 8 2 6
Values are means ± SD; 𝑛, number of participants; Tetra, tetraplegic; Para,
paraplegic; BMI, body mass index; TSI, time since injury.
profile in men and women [40] and central obesity in healthy
men [38].
The purpose of the current study was to quantify liver
adiposity in a chronic SCI population using FSF determined
by MRI. We furthermore aimed to investigate the relation-
ships between FSF and both metabolic and lipid profiles. The
hypothesis was that FSF would be positively related to serum
triglycerides (TG), free-fatty acids (FFA), and VAT and nega-
tively related to insulin sensitivity. It was of additional interest
to investigate the association between FSF and inflammatory
biomarkers. We are unaware of any study that has investi-
gated the association between liver adiposity and metabolic
dysfunction independent of VAT in persons with SCI.
2. Methods
This study was given ethical approval by the McGuire VA
Medical Center institutional review board. All procedures
were in accordance with theHelsinki Declaration of 1964 eth-
ical standards. Written informed consent was obtained from
each participant as part of a clinical trial (NCT01652040).
Data presented was obtained at baseline, prior to the inter-
vention, and the study protocol has been published separately
[41].
2.1. Participants. Twenty-two men ages 18–50 with motor
complete SCI were recruited for the study. Participant demo-
graphics are summarized in Table 1. Each of the participants’
time since injury (TSI) was greater than one year. Participants
were classified according to the American Spinal Injury
Association Impairment Scale (AIS) as A or B. Levels of
injury ranged from T11 to C5. Exclusion criteria included
known cardiovascular disease, uncontrolled type II diabetes
mellitus, or pressure sores stage II or greater. All participants
completed a physical and medical examination to determine
study eligibility. This examination included a neurological
assessment according to the International Standards for
Neurological Classification of SCI (ISNCSCI), including the
American Spinal Injury Association (ASIA) Impairment
Scale (AIS). Inclusion criteria included men with motor
complete SCI level C5-L2 greater than one year after injury,
ages 18–50.
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2.2. Metabolic Profile. Metabolic profile was assessed as
previously described [41, 42]. Blood samples were taken every
2 minutes before and 2-3 minutes after glucose injection
(0.3 g/kg) for 30minutes, followed by sampling every 5, 10, 20,
and 30 minutes ending at 180 minutes. Twenty minutes after
glucose injection insulin (0.02U/kg) was injected. Insulin
sensitivity (𝑆i) and glucose effectiveness (𝑆g) were deter-
mined using MinMod software (MinMod Inc., Pasadena,
CA) [43]. Three values for 𝑆i were excluded due to measure-
ment error. Fasted lipid profile and total testosterone levels
were measured prior to glucose injection. Non-high-density
lipoprotein cholesterol (non-HDL-C) is representative of
low-density lipoprotein cholesterol (LDL-C) and very low
LDL-C (VLDL-C). One participant’s values for both plasma
glucose and glycated hemoglobin (HbA1c) were inaccessible
due to a technical lab error and one participant did not
undergo any metabolic profile measurements.
2.3. Inflammatory Cytokines. Inflammatory cytokines were
measured from fasting serum samples with a specific ELISA
for human tumor necrosis factor alpha (TNF-𝛼) and for
human interleukin-6 (IL-6) according to the manufacturer’s
instructions (ALPCO). Data are expressed in picograms per
milliliter.
2.4. Magnetic Resonance Imaging (MRI). IP and OP images
were obtained with a 1.5 T scanner using an axial T1-
weighted fast spin-echo image acquisition (General Electric
Signa scanner, Milwaukee, WI, USA). Transverse slices were
taken from the xiphoid process to the femoral heads. The
legs and knees were strapped to prevent muscle spasms.
Participants were asked to hold their breath to reduce artifact
[8]. Parameters were as follows: repetition time, 140ms; echo
time, 4.3ms (IP), 2ms (OP); flip angle, 80∘; field of view,
42 cm; slice thickness, 0.8 cm; interslice space, 1.2 cm [8].MRI
data was not available for one participant, so only metabolic
and lipid data were analyzed for this individual.
Images were sequenced anatomically and analyzed using
specialized imaging software for MRI analysis (Win Vessel
2, Ronald Meyer, MSU, MI, USA). Calculation of VAT and
SAT has been detailed previously [10]. Briefly, an experienced
technician manually traced regions of interest using segmen-
tation and signal intensity to identify the fat and nonfat tissue.
Trunk cross-sectional area (CSA) refers to SAT and VAT, in
addition to other nonfat compartments such as bone and
organs.
2.5. Liver Cross-Sectional Area (CSA) and Fat Signal Fraction
(FSF). Three IP images were used from the start of the
anatomical sequence to analyze the liver at its largest size.
Each image’s IP was matched to its identical OP and all three
coupled images werematched among each participant as best
as possible. The technician traced around the whole liver in
the IP image excluding large veins and arteries (Figure 1(a)).
This trace was copied to its identical OP image (Figure 1(b)).
Signal intensity and CSA were recorded for both IP and OP
images. Liver CSA was measured by multiplying the total
number of pixels by the pixel size (field of view/matrix size)2.
The following equation [44] was used to calculate the liver
FSF:
FSF = Abs[(SIIP − SIOP)2 ∗ SIIP ] , (1)
where Abs is absolute value, SIIP is the signal intensity of the
liver in the IP image, and SIOP is the signal intensity of the
liver in the OP image. Two participants were excluded from
analysis due to poor image quality. FSF-VAT index was cal-
culated as (FSF + VAT)/SAT.
2.6. Statistics. IBM-SPSS version 23 (Armonk, NY) was
used for all statistical analyses. Differences between indi-
viduals with paraplegia (T4–T11) and tetraplegia (C5–C7)
were analyzed using independent 𝑡-tests. Bivariate Pearson
correlations were used to determine the relationship between
hepatic FSF and lipid and metabolic profile variables. Age,
level of injury (LOI), and TSI were accounted for by partial
correlations. Partial correlations were also used to account
for VAT and inflammatory cytokines in the relationships
between FSF and metabolic profile. Statistical significance
was determined at 𝑝 < 0.05. Data presented is mean ± stand-
ard deviation (SD).
3. Results
3.1. Participant Characteristics. The physical characteristics
of study participants are presented in Table 1. There were no
significant differences between individuals with tetraplegia
and paraplegia or between ethnic groups. Lipid profile,
metabolic profile, adipose tissue, inflammation, and liver
measurements are presented in Table 2.
Non-HDL-C and total cholesterol : HDL-C were signif-
icantly greater in individuals with tetraplegia compared to
those with paraplegia. There was a trend for higher fasting
glucose and HbA1c and lower 𝑆i in individuals with tetra-
plegia compared to those with paraplegia. Individuals with
tetraplegia had 36% less testosterone compared to those
with paraplegia. No significant differences were observed in
inflammatory cytokines, trunk CSA, SAT, or VAT.
3.2. Liver Cross-Sectional Area (CSA) and Fat Signal Fraction
(FSF). Liver CSA was not significantly different between
individuals with tetraplegia and those with paraplegia
(Table 2). Thirty percent of participants had an FSF greater
than 5%, with a range of 0.5–8.1%. Average hepatic FSF was3.7 ± 2.1%, with higher values in individuals with tetraplegia
(5.3 ± 2.1%) compared to individuals with paraplegia (2.9 ±1.6%; 𝑝 = 0.008).
3.3. Relationships among FSF and Lipid andMetabolic Profiles.
The relationships between FSF and lipid profile are shown
in Figure 2. FSF was positively related to TG (𝑟 = 0.54,𝑝 = 0.017) and non-HDL-C (𝑟 = 0.50, 𝑝 = 0.028). There
was no relationship between FSF and total cholesterol, LDL-
C, HDL-C, total cholesterol : HDL ratio, or FFA.The relation-
ships between FSF and metabolic profile are shown in
Figure 3. There were positive relationships between FSF, fast-
ing glucose, and HbA1c (𝑟 = 0.51, 𝑝 = 0.029 and 𝑟 = 0.51,
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Figure 1: MRI images were used to trace the liver using the in-phase (IP) image (a) and its identical out-phase (OP) image (b) for calculation
of the hepatic fat signal fraction (FSF).
Table 2: Lipid profile, glucose profile, ectopic adipose tissue, and inflammation in persons with motor complete SCI.
Total, n = 22 Tetra, n = 8 Para, n = 14
Lipid profile
Total cholesterol (mg/dl) 150.1 ± 29.0 160.4 ± 21.1 144.3 ± 31.9
TG (mg/dl) 111.1 ± 54.5 141.1 ± 68.2 93.9 ± 37.6
LDL-C (mg/dl) 92.6 ± 26.9 98.4 ± 23.2 89.3 ± 29.1
HDL-C (mg/dl) 35.0 ± 8.1 33.0 ± 6.5 36.1 ± 8.9
Non-HDL-C (mg/dl) 111.9 ± 32.3 127.4 ± 16.7 103.1 ± 36.2∗
Total cholesterol: HDL-C 4.4 ± 1.0 4.9 ± 0.7 4.1 ± 1.0∗
FFA (𝜇M/L) 363.7 ± 188.8 394.1 ± 216.6 346.3 ± 177.2
Metabolic profile
Fasting glucose (mg/dl) 107.1 ± 13.0, 𝑛 = 21 114.5 ± 14.54 102.5 ± 9.8, 𝑛 =13∧
𝑆i ((mU/L)−1min−1) 8.62 ± 6.28, 𝑛 = 19 4.61 ± 6.07, n = 6 10.47 ± 5.67, 𝑛 = 13∧𝑆g (min−1) 0.020 ± 0.009 0.017 ± 0.003 0.022 ± 0.011
HbA1c (%) 5.35 ± 0.45, 𝑛 = 21 5.61 ± 0.50 5.19 ± 0.34, 𝑛 = 13∧
Testosterone (ng/dl) 424.4 ± 159.1 345.3 ± 125.5 469.6 ± 162.3∧
SAT and VAT
Trunk CSA (cm2) 654.4 ± 139.6 664.7 ± 166.8 648.5 ± 128.0
SAT (cm2) 157.0 ± 79.6 163.5 ± 103.2 153.4 ± 66.7
VAT (cm2) 105.4 ± 63.9 117.5 ± 57.2 98.4 ± 68.6
Inflammation
TNF𝛼 (pg/ml) 15.3 ± 8.0 16.0 ± 8.2 14.9 ± 8.1
IL-6 (pg/ml) 5.89 ± 6.77 5.03 ± 5.39 6.39 ± 7.59
Liver analysis (𝑛) 20 7 13
FSF (%) 3.73 ± 2.10 5.34 ± 2.05 2.86 ± 1.59∗
Liver CSA (cm2) 163.4 ± 31.8 158.0 ± 30.5 166.3 ± 33.4
Values are means ± SD; 𝑛, number of participants; Tetra, tetraplegic; Para, paraplegic; LDL, low-density lipoprotein cholesterol; HDL-C, high-density
lipoprotein cholesterol; FFA, free-fatty acids; 𝑆i, insulin sensitivity; 𝑆g, glucose effectiveness; HbA1c, glycated hemoglobin; SAT, subcutaneous adipose tissue;
VAT, visceral adipose tissue; TNF𝛼, tumor necrosis factor alpha; IL-6, interleukin-6; FSF, fat signal fraction; CSA, cross-sectional area; ∧𝑝 ≤ 0.1, ∗𝑝 < 0.05
tetra versus para.
BioMed Research International 5
0
50
100
150
200
250
300
0 2 4 6 8
Tr
ig
ly
ce
rid
es
 (m
g/
dl
)
Hepatic FSF (%)
r = 0.54
p = 0.02
0
20
40
60
80
100
120
140
160
180
200
0 2 4 6 8
Hepatic FSF (%)
r = 0.50
p = 0.03
N
on
-H
D
L-
C 
(m
g/
dl
)
Figure 2: Relationships between hepatic fat signal fraction (FSF) and lipid profile. TG, triglycerides and Non-HDL-C, high-density
lipoprotein cholesterol.
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Figure 3: Relationships between hepatic fat signal fraction (FSF) and metabolic profile. Fasting glucose, HbA1c, glycated hemoglobin,
testosterone, and 𝑆i, insulin sensitivity.
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Table 3: Relationships and partial correlations between FSF, lipid
panel, glucose profile, and inflammation accounting for age, level of
injury (LOI), and time since injury (TSI).
Pearson Partial(age)
Partial
(LOI)
Partial
(TSI)
Non-HDL-C (mg/dl) 0.503∗ 0.350∗ 0.366 0.509
TG (mg/dl) 0.538∗ 0.515∗ 0.378 0.720∗∗
𝑆i ((mU/L)−1min−1) −0.605∗ −0.553∗ −0.423 −0.618∗
Fasting glucose
(mg/dl) 0.513∗ 0.478∧ 0.380 0.518∗
HbA1c (%) 0.506∗ 0.470∧ 0.370 0.511∗
Testosterone (ng/dl) −0.466∗ −0.475∧ −0.345 −0.467∧
VAT (cm2) 0.480∗ 0.531∗ 0.489∗ 0.555∗
TNF-𝛼 (pg/ml) 0.598∗ 0.531∗ 0.629∗ 0.617∗
HDL-C; high-density lipoprotein cholesterol; TG, triglycerides; 𝑆i, insulin
sensitivity; HbA1c, glycated hemoglobin; VAT, visceral adipose tissue; TNF-
𝛼, tumor necrosis factor alpha. ∧𝑝 ≤ 0.1, ∗𝑝 < 0.05, and ∗∗𝑝 < 0.01.
𝑝 = 0.032, resp.). FSF was negatively related to 𝑆i (𝑟 = −0.61,𝑝 = 0.013) and testosterone (𝑟 = −0.47,𝑝 = 0.044).Therewas
no relationship between FSF and glucose effectiveness (𝑆g).
When ectopic adipose tissue (FSF + VAT) was normalized
to SAT (FSF-VAT index), these relationships were no longer
significant.Therewere, however, trends between the FSF-VAT
index and fasting glucose, HbA1c, and FFA (𝑟 = 0.43 𝑝 =0.073, 𝑟 = 0.44 𝑝 = 0.069, and 𝑟 = 0.49 𝑝 = 0.067, resp.).
3.4. Relationships among FSF, Trunk Adipose Tissue, and
Inflammation. The relationships between FSF, trunk CSA,
andVAT are shown in Figure 4(a).There was a trend between
FSF and trunk CSA (𝑟 = 0.38, 𝑝 = 0.094). There was a signi-
ficant positive relationship between FSF and VAT (𝑟 =0.48, 𝑝 = 0.032), but no significant relationship with SAT.
Figure 4(b) shows the relationships between ectopic adipose
tissue and inflammation. FSFwas strongly related to theTNF-𝛼 (𝑟 = 0.62, 𝑝 = 0.012) but not IL-6. TNF-𝛼 was also
positively related to VAT (𝑟 = 0.48, 𝑝 = 0.028). Furthermore,
the relationships between the FSF-VAT index and inflam-
matory cytokines were not significant.
3.5. Relationships Independent of Age, Level of Injury (LOI),
and Time since Injury (TSI). Table 3 shows the relationships
between FSF andmetabolic and lipid profiles after accounting
for age, LOI, and TSI.The relationships between FSF and TG,𝑆i, VAT, and TNF-𝛼 remained significant after accounting for
age and TSI. Non-HDL-C remained significant after account-
ing for age but was no longer significant after considering
TSI. Trends were seen between FSF and fasting glucose (𝑝 =0.053), HbA1c (𝑝 = 0.057), and testosterone (𝑝 = 0.077)
after accounting for age. Fasting glucose andHbA1c remained
significantly related to FSF after accounting for TSI. All
relationships were no longer significant after accounting for
LOI, with the exception of VAT and TNF-𝛼.
Table 4 shows the relationships between FSF and meta-
bolic profile after accounting for VAT, TNF-𝛼 and IL-6.These
relationships remained significant after accounting for VAT,
Table 4: Relationships and partial correlations between FSF and
metabolic profile accounting for VAT and inflammatory cytokines.
Pearson Partial(VAT)
Partial
(TNF-𝛼) Partial(IL-6)
𝑆i −0.605∗ −0.605∗ −0.361 0.054
Fasting glucose 0.513∗ 0.502∗ 0.331 −0.378
HbA1c 0.506∗ 0.532∗ 0.312 −0.382
Testosterone −0.466∗ −0.553∗ −0.420 0.063
FSF, fat signal fraction; 𝑆i, insulin sensitivity; HbA1c, glycated hemoglobin;
VAT, visceral adipose tissue; TNF-𝛼, tumor necrosis factor alpha; IL-6,
interleukin-6. ∗𝑝 < 0.05.
but were no longer significant after accounting for inflam-
matory cytokines.
4. Discussion
Individuals with SCI are at greater risk for several carbohy-
drate and lipid disorders, such as type II diabetes, metabolic
syndrome, and obesity, compared to the general population
[1, 3]. Previous studies have shown the link between increased
ectopic adipose tissue, inflammation, andmetabolic dysfunc-
tion in able-bodied individuals [18]. Despite this, few studies
have investigated liver adiposity as a risk factor for metabolic
dysfunction after SCI. In the current study, we quantified
FSF noninvasively by MRI in a chronic SCI population.
FSF was linked to several metabolic variables independent
of age, TSI, and VAT. Moreover, FSF was independently
related to VAT and TNF-𝛼, suggesting that FSF is linked to
inflammation. Liver adiposity may be an independent risk
factor for metabolic dysfunction after SCI.
4.1. FSF and Lipid and Metabolic Profiles. After passing
through the intestines, nutrients including glucose, fatty
acids, and amino acids travel through the hepatic portal
vein upon delivery to the liver, which regulates metabolic
homeostasis [45]. Here, triglycerides are synthesized from
glucose during lipogenesis and are transported through the
blood and to the muscle by VLDL-C [45]. Increased hepatic
lipids may impair the ability of insulin to regulate gluconeo-
genesis; however, lipogenesis remains unaffected [45, 46]. In
the current study, the association between VLDL-C and liver
adiposity is exemplified by the positive relationship between
FSF and non-HDL-C, which confirms previous reports in
able-bodied individuals [47, 48]. Although we did not mea-
sure VLDL-C separately from LDL-C, no relationship was
observed between FSF and HDL-C or LDL-C, highlighting
the importance of VLDL-C related to liver metabolism [49].
Surprisingly, there was no relationship between FSF and FFA
in the current study, which is in contrast to previous studies
of persons with NAFLD [50]. However, the cumulative effect
of VAT and FSF (FSF-VAT index) resulted in a stronger
association with FFA in the current study.
FSF was positively related to blood glucose levels and
negatively related to insulin sensitivity in the current study,
in agreement with previous research studies [47, 51, 52]. The
progression of insulin resistance may explain these findings.
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Figure 4: Relationships between hepatic fat signal fraction (FSF), trunk cross-sectional area (CSA), and visceral adipose tissue (VAT; (a))
and inflammation and ectopic adipose tissue ((b); hepatic FSF or VAT). TNF𝛼, tumor necrosis factor alpha.
Insulin resistance inhibits skeletal muscle glucose uptake by
impairing glucose transporter 4 (GLUT4) translocation to
the membrane [46]. This results in increased blood glucose
and delivery back to the liver, where it may be stored as
adipose tissue due to de novo lipogenesis. Furthermore,
insulin resistance stimulates the actions of hormone sensitive
lipase, which is the rate-limiting enzyme for lipolysis [53]. An
increase in lipolysis and increased delivery of dietary glucose
combined with increased lipogenesis promotes reesterifica-
tion of lipids in liver andmuscle, further exacerbating insulin
resistance.
Increased ectopic adipose tissue such as VAT contributes
to metabolic dysfunction. More recently, there has been
speculation regarding the relative contributions of VAT and
liver adiposity to the development of metabolic disease [47,
54]. Previous studies have shown that liver adiposity pre-
dicted metabolic dysfunction [55] and insulin resistance [54]
independent of VAT.The current study extends these findings
to the SCI population. The associations between FSF and
metabolic regulation remained significant when VAT was
accounted for. Additionally, the cumulative effect of FSF and
VAT (FSF-VAT index) resulted in less significant relationships
with metabolic profile compared to FSF alone. Collectively,
these findings suggest that liver adipose tissue was negatively
associatedwithmetabolic profile independently ofVAT in the
current study. This highlights the importance of preventing
and/or managing liver adiposity, in addition to VAT, in
order to avert metabolic dysfunction. Liver adiposity may
be decreased by weight loss, through exercise and diet,
or by pharmacological intervention such as metformin or
pioglitazone [44].
Autonomic dysfunction may contribute to decreased
hormone release such as testosterone and further exacerbate
metabolic dysfunction and liver adiposity after SCI [9, 56].
Low testosterone (<325 ng/dl) has been shown to be linked
to metabolic diseases like type II diabetes, metabolic syn-
drome, and insulin resistance in able-bodied populations
[57–60]. Studies using testosterone replacement therapy
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have found that testosterone increases lean mass, reduces
fat mass, and improves metabolic profile [61, 62]. Twenty
percent of the participants in the current study had low
testosterone. Interestingly, this inverse association between
FSF and testosterone was independent of VAT. Similarly,
Barbonetti et al. found that the risk for NAFLD increased for
every 1 ng/dl decline in testosterone in individuals with SCI
[30].
4.2. FSF, Trunk Adipose Tissue, and Inflammation. Based on
previous findings, eighty-two percent of participants in the
current study are obese based on VAT cutoff > 100 cm2 [63]
despite having a normal BMI. This cutoff was established by
using DXA and CT scan measurements of VAT in persons
with SCI [63]. We have previously shown that individuals
with chronic SCI who have VAT CSA > 100 cm2 are likely
to experience insulin resistance [10]. Previous studies have
shown that VAT positively correlates with liver adiposity
and that these two sources of ectopic adipose tissue have a
negative effect on insulin sensitivity [17, 47, 64]. The current
study extends these findings to individuals with SCI. The
mechanisms underlying this process remain unclear and
may include signaling by lipid intermediates (e.g., diacyl-
glycerol and ceramides) and increased inflammation [46].
One hypothesis for the link between VAT, liver adipose
tissue, and metabolic dysfunction is that release of inflam-
matory cytokines such as TNF-𝛼 and IL-6 from activated
macrophages invades ectopic adipose tissue [65, 66] and
causes prolonged metabolic stress. TNF-𝛼 has been shown
to inhibit insulin signaling via insulin receptor substrate
1 (IRS1) and may increase adipose lipolysis [46]. Previous
studies have found that liver adiposity and inflammation
were positively related, which supports this hypothesis [17,
67, 68]. The current study found an independent posi-
tive relationship between FSF and TNF-𝛼. VAT was also
strongly associated with TNF-𝛼. It is interesting to note
that the strong associations between liver adiposity and
metabolic profile were no longer significant after account-
ing for TNF-𝛼, which may support the hypothesis that
liver adiposity exerts its negative effects on metabolism via
inflammatory cytokines. Future studies may want to fur-
ther investigate the mechanisms underlying the relationship
between liver adiposity and inflammation in a SCI popula-
tion.
5. Limitations
The study criteria excluded individuals with uncontrolled
diabetes or known cardiovascular disease [41]. Because
the study intervention included testosterone replacement
therapy, only men were included. For these reasons, the
current findings may not be generalizable to the entire
SCI population; however, individuals with motor complete
SCI represent ∼45% of the SCI population [69]. Because
the study was not powered to investigate liver adiposity,
confounding variables were not accounted for during MRI
acquisition. Furthermore, the use ofMRI is limited to clinical
settings and requires significant funding for research use,
which may make the current findings difficult to replicate
in a large cohort of individuals with SCI. While this data
should be interpreted with caution, it may be used to
drive future research hypotheses. Future studies may war-
rant the use of a larger sample of both men and women
with a range of BMI as well as those with metabolic dis-
orders.
6. Conclusions
Liver adiposity was quantified noninvasively in persons
with chronic SCI. Increased FSF was associated with lipid
and metabolic variables such as increased TG, non-HDL-C,
fasting glucose, andHbA1c and decreased 𝑆i and testosterone.
Increased FSF was also associated with increased VAT and
TNF-𝛼, which was independent of age, LOI, and TSI. Associ-
ations between FSF and metabolic profile were independent
of VAT but not inflammation, highlighting that inflammation
may be the mechanism by which liver adiposity negatively
impacts metabolic profile in this population. This highlights
the importance of quantifying liver adiposity after SCI in
order to prevent the development of NAFLD.
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